Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.

Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -527 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -82%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%

Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 50%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.
3 Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -527 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -82%
5 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%
7 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%
9 Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

HNGE in ETFs

Weight = HNGE's share of each fund

VTI0.00%
ITOT0.00%
VB0.02%
IHF0.38%
ESML0.07%
SCHA0.05%
VBR0.04%
VHT0.03%
+1 more covered ETF

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 7/1/2026

Hinge Health (HNGE) stock has gained about 120% since 3/31/2026 because of the following key factors:

1. Exceptional Fiscal Q1 2026 Financial Results Exceeding Expectations.

Hinge Health announced its financial results for fiscal Q1 2026 (ended March 31, 2026) on May 5, 2026, reporting revenue of $182 million, a substantial 47% year-over-year increase compared to fiscal Q1 2025's $124 million. This significantly surpassed the company's guidance range of $171 million to $173 million. The company also delivered an earnings per share (EPS) of $0.45, considerably beating the analyst consensus estimate of $0.12. Additionally, Hinge Health achieved a 25% non-GAAP operating margin and generated $42 million in free cash flow, indicating strong operational efficiency. This strong financial outperformance and efficiency fueled investor confidence, driving the stock's upward trend.

2. Upward Revision of Fiscal Q2 and Full-Year 2026 Guidance.

Building on its strong performance, Hinge Health further raised its financial guidance for both fiscal Q2 2026 and the full year 2026 on June 9, 2026. For fiscal Q2 2026, the company now expects revenue between $200 million and $202 million, representing approximately 45% year-over-year growth at the midpoint, which exceeded Wall Street's estimate of $195 million. The full-year 2026 revenue guidance was increased to a range of $818 million to $824 million, marking a $20 million increase at the midpoint from previous guidance and reflecting 40% year-over-year growth. The company also projected a non-GAAP operating margin of 27% at the midpoint for the full year. These significantly raised financial targets, coupled with an Investor Day on June 10, 2026, to discuss future strategy, underscored strong business momentum and scalability, leading to increased investor optimism.

Show more
Updated on 7/1/2026

Hinge Health (HNGE) stock has gained about 120% since 3/31/2026 because of the following key factors:

1. Exceptional Fiscal Q1 2026 Financial Results Exceeding Expectations.

Hinge Health announced its financial results for fiscal Q1 2026 (ended March 31, 2026) on May 5, 2026, reporting revenue of $182 million, a substantial 47% year-over-year increase compared to fiscal Q1 2025's $124 million. This significantly surpassed the company's guidance range of $171 million to $173 million. The company also delivered an earnings per share (EPS) of $0.45, considerably beating the analyst consensus estimate of $0.12. Additionally, Hinge Health achieved a 25% non-GAAP operating margin and generated $42 million in free cash flow, indicating strong operational efficiency. This strong financial outperformance and efficiency fueled investor confidence, driving the stock's upward trend.

2. Upward Revision of Fiscal Q2 and Full-Year 2026 Guidance.

Building on its strong performance, Hinge Health further raised its financial guidance for both fiscal Q2 2026 and the full year 2026 on June 9, 2026. For fiscal Q2 2026, the company now expects revenue between $200 million and $202 million, representing approximately 45% year-over-year growth at the midpoint, which exceeded Wall Street's estimate of $195 million. The full-year 2026 revenue guidance was increased to a range of $818 million to $824 million, marking a $20 million increase at the midpoint from previous guidance and reflecting 40% year-over-year growth. The company also projected a non-GAAP operating margin of 27% at the midpoint for the full year. These significantly raised financial targets, coupled with an Investor Day on June 10, 2026, to discuss future strategy, underscored strong business momentum and scalability, leading to increased investor optimism.

3. Strategic Product Expansion and Robust Commercial Momentum.

Hinge Health demonstrated strong commercial momentum and strategic product innovation during this period. The company launched a comprehensive Migraine Care Program, receiving FDA clearance for its Enso device, and rapidly secured early adoption by 125 clients, covering over 2 million eligible lives. Furthermore, Hinge Health expanded its HingeSelect platform to include orthopedic surgery, offering a fully integrated musculoskeletal (MSK) care solution that now encompasses physical therapy, specialist evaluations, prehabilitation, surgery, and post-operative recovery. These product enhancements and the reported materially larger sales pipeline compared to fiscal Q1 2025, driven by higher member conversion and performance across its client base, highlighted the company's ability to drive growth and expand its market footprint in the digital health sector.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 120.6% change in HNGE stock from 3/31/2026 to 7/1/2026 was primarily driven by a 97.7% change in the company's P/S Multiple.
(LTM values as of)33120267012026Change
Stock Price ($)38.5685.07120.6%
Change Contribution By: 
Total Revenues ($ Mil)5886469.9%
P/S Multiple5.210.397.7%
Shares Outstanding (Mil)80791.5%
Cumulative Contribution120.6%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2026 to 7/1/2026
ReturnCorrelation
HNGE120.6% 
Market (SPY)14.7%22.0%
Sector (XLV)8.8%18.4%

Fundamental Drivers

The 83.1% change in HNGE stock from 12/31/2025 to 7/1/2026 was primarily driven by a 82.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)123120257012026Change
Stock Price ($)46.4585.0783.1%
Change Contribution By: 
Total Revenues ($ Mil)35564682.2%
P/S Multiple9.010.315.3%
Shares Outstanding (Mil)6979-12.8%
Cumulative Contribution83.1%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 7/1/2026
ReturnCorrelation
HNGE83.1% 
Market (SPY)9.7%28.4%
Sector (XLV)3.5%16.8%

Fundamental Drivers

The 64.4% change in HNGE stock from 6/30/2025 to 7/1/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)63020257012026Change
Stock Price ($)51.7585.0764.4%
Change Contribution By: 
Total Revenues ($ Mil)6460.0%
P/S Multiple10.30.0%
Shares Outstanding (Mil)6979-12.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2025 to 7/1/2026
ReturnCorrelation
HNGE64.4% 
Market (SPY)21.7%24.5%
Sector (XLV)19.9%6.6%

Fundamental Drivers

null
null

Market Drivers

6/30/2023 to 7/1/2026
ReturnCorrelation
HNGE  
Market (SPY)74.2%24.9%
Sector (XLV)25.8%6.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HNGE Return----24%79%121%
Peers Return-46%-65%-39%-63%-28%22%-96%
S&P 500 Return27%-19%24%23%16%10%100%

Monthly Win Rates [3]
HNGE Win Rate----50%67% 
Peers Win Rate31%25%44%33%28%50% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
HNGE Max Drawdown------37% 
Peers Max Drawdown-74%-69%-71%-76%-74%-40% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/1/2026 (YTD)

How Low Can It Go

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to TDOC, AMWL, DRIO

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to TDOC, AMWL, DRIO

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Hinge Health (HNGE)

Hinge Health (HNGE) is a digital health company focused on transforming musculoskeletal (MSK) care by leveraging technology to improve outcomes, experience, and costs. The company's vision is to build a new health system that scales and automates care for joint and muscle health, addressing everything from acute injury and chronic pain to post-surgical rehabilitation. By automating most aspects of care and developing novel billing methods, Hinge Health aims to overcome common healthcare challenges where new technologies often fail to lower costs or improve clinical outcomes effectively.

The core of Hinge Health's offering is a personalized, largely automated MSK care platform accessible through an on-demand app. Key technologies include their AI-powered motion tracking system, TrueMotion, and a proprietary FDA-cleared electrical nerve stimulation wearable device, Enso. This technology is supported by an AI-assisted care team comprising licensed physical therapists, physicians, and health coaches. The platform significantly reduces human care team hours—by approximately 95% compared to traditional physical therapy according to 2024 estimates—while delivering engaging, easy-to-use, and accessible exercise therapy that can improve pain and function and reduce the need for surgeries.

Hinge Health primarily serves self-insured employers, including a significant portion of Fortune 100 and Fortune 500 companies, as well as public sector entities and labor unions. The company employs an efficient go-to-market strategy, working directly with clients and partnering with major health plans, pharmacy benefit managers (PBMs), and third-party administrators (TPAs) to streamline adoption. With a recurring revenue business model based on average three-year contracts, Hinge Health boasts a high client retention rate of 98% and a net dollar retention of 117% as of December 31, 2024, demonstrating strong client satisfaction and growth potential within its vast addressable market.

AI Analysis | Feedback

Livongo for musculoskeletal health

Peloton for medical physical therapy

AI Analysis | Feedback

  • Digital Musculoskeletal (MSK) Care Service: A comprehensive, AI-powered virtual program that provides personalized and largely automated care for joint and muscle health, spanning prevention, acute injury, chronic pain, and post-surgical rehabilitation.
  • TrueMotion AI-powered Motion Tracking Technology: An integrated technology within their service that utilizes AI for real-time exercise feedback and tracks member progress, enabling scalable and personalized therapy.
  • Enso Electrical Nerve Stimulation Wearable Device: A proprietary, FDA-cleared wearable device seamlessly integrated into the service, delivering non-addictive and non-invasive pain relief via electrostimulation.

AI Analysis | Feedback

Hinge Health (HNGE) primarily sells to other companies.

The company's major customers are:

  • Self-insured employers, including many of the nation’s leading enterprises across a broad range of industries and sizes. As of December 31, 2024, Hinge Health had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies.
  • Public sector self-insured employers, such as state and local city governments and labor unions.

While Hinge Health partners with major national health plans and PBMs to facilitate access to clients, and is expanding to serve health plans' fully-insured and Medicare Advantage populations directly, its primary clients are explicitly stated as self-insured employers.

The provided text does not list specific names of the Fortune 100, Fortune 500, or other employer clients. Therefore, specific customer company names and their symbols cannot be provided.

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel Perez, Co-Founder and Chief Executive Officer

Daniel Perez co-founded Hinge Health in 2014. He holds a B.S. in Biology from Westminster University and completed a DPhil (PhD) in Biochemistry from the University of Oxford. Prior to Hinge Health, he co-founded Marblar and the Oxbridge Biotech Roundtable. He was inspired to start Hinge Health with Gabriel Mecklenburg due to their personal experiences with musculoskeletal injuries.

James Budge, Chief Financial Officer

James Budge joined Hinge Health as Chief Financial Officer in March 2023. He brings 25 years of CFO experience across various public and private high-growth technology companies. His previous CFO roles include Automation Anywhere, Pluralsight, Anaplan, Genesys Cloud Services, and Rovi Corporation. Budge has a track record of raising capital, taking companies public, and overseeing numerous acquisitions. He holds a B.S. in Accounting from Brigham Young University. His career has involved accelerating growth for public and late-stage private companies.

Gabriel Mecklenburg, Co-Founder and Executive Chairman

Gabriel Mecklenburg is the Co-Founder and Executive Chairman of Hinge Health, having also served as Chief Operating Officer from October 2014 to February 2021. He co-founded Marblar and Oxbridge Biotech Roundtable Ltd. He holds an M.Sc. in Materials Science from the University of Cambridge and an M. Phil. in Bioengineering from Imperial College London.

Jim Pursley, President

Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer of Livongo Health. He also held various executive positions at Care Innovations and GE HealthCare Technologies. He earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.

Dr. Jeff Krauss, Chief Medical Officer

Dr. Jeff Krauss is the Chief Medical Officer at Hinge Health, a role he assumed in September 2018.

AI Analysis | Feedback

The key risks to Hinge Health's business include:

  1. Challenges with Healthcare Reimbursement and Regulatory Environment: Hinge Health's business model relies on developing "novel billing methods" and partnering with various entities like health plans and pharmacy benefit managers (PBMs) to navigate the complex healthcare reimbursement framework. The healthcare industry is heavily regulated, and any changes to reimbursement policies, challenges in gaining acceptance for their billing methods, or difficulties in expanding into new, highly regulated segments like fully-insured and Medicare Advantage populations and federal insurance plans, could significantly impact their revenue and growth trajectory.
  2. Dependence on AI-Powered Technology Efficacy and Member Engagement: Hinge Health's core value proposition is built on its AI-powered motion tracking technology (TrueMotion) and proprietary FDA-cleared wearable device (Enso), which largely automate care for joint and muscle health and aim to reduce human care team hours by approximately 95%. A significant risk lies in the continuous efficacy of these technologies in delivering superior clinical outcomes, maintaining high member satisfaction, and sustaining member engagement, particularly given the inherent difficulty of automating unstructured physical tasks in healthcare. Any technical failures, lack of desired clinical results, or a decline in member trust and adoption could undermine the company's value proposition.
  3. Intense Competition and Market Penetration Challenges: While Hinge Health operates in a "massive" musculoskeletal (MSK) market, the healthcare industry has "no shortage of new technologies," implying a highly competitive landscape. Despite significant client retention rates and contracts with a large percentage of Fortune 100 and 500 companies, Hinge Health's current contracted lives represent only 5% of its total addressable market. The company faces the ongoing challenge of effectively competing with existing solutions and new market entrants, and efficiently penetrating the remaining 95% of the market to sustain its growth.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for Hinge Health's main products and services, which include its digital musculoskeletal (MSK) care platform, is approximately 400 million lives in the U.S.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Hinge Health (HNGE)

Hinge Health anticipates several key drivers for its revenue growth over the next 2-3 years, primarily stemming from its extensive market opportunity, strategic partnerships, and expansion into new customer segments.
  1. Growth in contracted lives and client acquisition: Hinge Health currently serves approximately 20 million contracted lives, which represents only 5% of its total addressable market. This leaves substantial room for growth through acquiring new self-insured employers and increasing penetration within the Fortune 100 and Fortune 500 companies, where it already has significant presence but still opportunities to expand.
  2. Expansion into new market segments: The company is in the early stages of broadening its reach beyond self-insured employers to serve fully-insured and Medicare Advantage populations of health plans, as well as federal insurance plans. This strategic expansion into new payer types opens up large, previously untapped revenue streams.
  3. Deepening engagement and penetration within existing client base: Hinge Health benefits from a recurring revenue model, demonstrated by a net dollar retention of 117% as of December 31, 2024, and a 12-month client retention rate of 98%. This indicates a strong ability to enroll, engage, and re-engage eligible members within its existing client contracts, leading to organic revenue growth over the typical three-year contract term.
  4. Leveraging and expanding its partner network: With over 50 partners, including the five largest national health plans and top three PBMs, Hinge Health's partner network is a crucial component of its efficient go-to-market strategy. These partnerships reduce friction in contracting, procurement, and onboarding, facilitating the efficient provision of its platform to clients and members, thereby accelerating client acquisition and growth in contracted lives.

AI Analysis | Feedback

null

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Price85.079.109.376.759.23
Mkt Cap6.70.10.20.00.1
Rev LTM6462,51423722442
Op Inc LTM-527-157-92-37-125
FCF LTM203127-45-2650
FCF 3Y Avg-169-113-32-32
CFO LTM210288-42-2692
CFO 3Y Avg-311-104-32-32

Growth & Margins

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Rev Chg LTM49.8%-1.5%-9.3%-17.3%-5.4%
Rev Chg 3Y Avg-0.7%-4.9%-3.6%-3.6%
Rev Chg Q47.2%-2.5%-17.9%-31.2%-10.2%
QoQ Delta Rev Chg LTM9.9%-0.6%-4.8%-9.6%-2.7%
Op Inc Chg LTM-4,269.1%15.8%46.6%36.5%26.2%
Op Inc Chg 3Y Avg-11.0%28.1%11.6%11.6%
Op Mgn LTM-81.6%-6.3%-38.9%-163.9%-60.2%
Op Mgn 3Y Avg-39.0%-7.4%-69.5%-217.9%-54.3%
QoQ Delta Op Mgn LTM11.3%0.2%3.3%-3.2%1.8%
CFO/Rev LTM32.4%11.5%-17.6%-116.0%-3.1%
CFO/Rev 3Y Avg-12.1%-41.1%-136.0%-41.1%
FCF/Rev LTM31.4%5.0%-18.8%-116.7%-6.9%
FCF/Rev 3Y Avg-6.6%-44.6%-137.3%-44.6%

Valuation

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Cap6.70.10.20.00.1
P/S10.30.00.72.11.4
P/Op Inc-12.7-0.3-1.7-1.3-1.5
P/EBIT-12.7-0.3-1.7-1.3-1.5
P/E-13.1-0.3-1.8-1.1-1.4
P/CFO31.90.2-3.7-1.8-0.8
Total Yield-7.6%-315.0%-56.5%-89.5%-73.0%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-338.8%-72.2%-1,580.3%-72.2%
D/E0.019.10.00.70.4
Net D/E-0.05.3-1.10.10.0

Returns

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
1M Rtn39.6%15.0%3.5%-12.3%9.3%
3M Rtn121.0%72.3%77.1%-16.7%74.7%
6M Rtn83.1%30.0%90.8%-40.7%56.6%
12M Rtn87.8%6.1%11.5%-52.5%8.8%
3Y Rtn126.5%-64.1%-77.7%-91.6%-70.9%
1M Excs Rtn41.2%16.6%5.1%-10.8%10.8%
3M Excs Rtn106.0%52.3%63.5%-30.5%57.9%
6M Excs Rtn72.3%23.0%96.2%-44.0%47.6%
12M Excs Rtn43.8%-16.1%-15.2%-70.2%-15.7%
3Y Excs Rtn53.6%-134.7%-150.3%-163.4%-142.5%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil202520242023
Single Segment588390293
Total588390293


Net Income by Segment
$ Mil202520242023
Single Segment-528-12-108
Total-528-12-108


Price Behavior

Price Behavior
Market Price$85.07 
Market Cap ($ Bil)6.7 
First Trading Date05/22/2025 
Distance from 52W High0.0% 
   50 Days200 Days
DMA Price$45.78$42.02
DMA Trendupup
Distance from DMA85.8%102.5%
 3M1YR
Volatility49.5%61.1%
Downside Capture-99.65121.97
Upside Capture239.72168.76
Correlation (SPY)24.9%24.7%
HNGE Betas & Captures as of 6/30/2026

 1M2M3M6M1Y3Y
Beta1.090.870.871.171.24-0.31
Up Beta0.872.231.420.931.22-0.56
Down Beta-0.210.22-0.281.230.200.30
Up Capture471%329%278%217%278%31%
Bmk +ve Days11244067140429
Stock +ve Days14294474133145
Down Capture-53%-152%-94%72%131%66%
Bmk -ve Days10172358112321
Stock -ve Days7121951115127

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE70.6%62.3%1.10-
Sector ETF (XLV)20.0%15.5%0.986.2%
Equity (SPY)21.8%12.5%1.3024.2%
Gold (GLD)21.7%27.7%0.692.7%
Commodities (DBC)21.4%18.6%0.90-5.1%
Real Estate (VNQ)13.0%13.7%0.656.5%
Bitcoin (BTCUSD)-45.0%42.6%-1.2811.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE18.6%63.0%1.48-
Sector ETF (XLV)6.7%14.8%0.275.8%
Equity (SPY)13.5%17.1%0.6124.6%
Gold (GLD)17.4%18.3%0.772.3%
Commodities (DBC)6.8%19.5%0.25-5.9%
Real Estate (VNQ)2.8%18.8%0.059.2%
Bitcoin (BTCUSD)11.9%53.7%0.4111.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE8.9%63.0%1.48-
Sector ETF (XLV)10.4%16.6%0.515.8%
Equity (SPY)15.4%18.0%0.7324.6%
Gold (GLD)11.9%16.1%0.602.3%
Commodities (DBC)5.6%18.0%0.24-5.9%
Real Estate (VNQ)5.4%20.7%0.229.2%
Bitcoin (BTCUSD)56.6%66.3%0.9711.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date6152026
Short Interest: Shares Quantity5.8 Mil
Short Interest: % Change Since 531202642.6%
Average Daily Volume2.1 Mil
Days-to-Cover Short Interest2.8 days
Basic Shares Quantity78.6 Mil
Short % of Basic Shares7.3%

Earnings Returns History

Updated 6/8/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/5/202610.2%11.0%26.6%
2/10/202617.3%22.7%34.5%
11/4/2025-15.1%-17.1%-6.4%
8/5/202525.6%16.1%16.2%
SUMMARY STATS   
# Positive333
# Negative111
Median Positive17.3%16.1%26.6%
Median Negative-15.1%-17.1%-6.4%
Max Positive25.6%22.7%34.5%
Max Negative-15.1%-17.1%-6.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/5/202610.2%11.0%26.6%
2/10/202617.3%22.7%34.5%
11/4/2025-15.1%-17.1%-6.4%
8/5/202525.6%16.1%16.2%
SUMMARY STATS   
# Positive333
# Negative111
Median Positive17.3%16.1%26.6%
Median Negative-15.1%-17.1%-6.4%
Max Positive25.6%22.7%34.5%
Max Negative-15.1%-17.1%-6.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202503/03/202610-K
09/30/202511/07/202510-Q
06/30/202508/11/202510-Q
03/31/202505/23/2025424B4
Collapse to Preview
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202503/03/202610-K
09/30/202511/07/202510-Q
06/30/202508/11/202510-Q
03/31/202505/23/2025424B4

Recent Forward Guidance

Updated 6/1/2026

Latest: Q1 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Revenue194.00 Mil195.00 Mil196.00 Mil   
Q2 2026 Non-GAAP Income from Operations47.00 Mil48.00 Mil49.00 Mil   
Q2 2026 Non-GAAP Operating Margin 25.0%    
2026 Revenue798.00 Mil801.00 Mil804.00 Mil8.7% RaisedGuidance: 737.00 Mil for 2026
2026 Non-GAAP Income from Operations205.00 Mil210.00 Mil215.00 Mil36.8% RaisedGuidance: 153.50 Mil for 2026
2026 Non-GAAP Operating Margin 26.0% 23.8%5.0%RaisedGuidance: 21.0% for 2026

Prior: Q4 2025 Earnings Reported 2/10/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue171.00 Mil172.00 Mil173.00 Mil10.3% Higher NewGuidance: 156.00 Mil for Q4 2025
Q1 2026 Non-GAAP Income from Operations30.00 Mil31.00 Mil32.00 Mil-11.4% Lower NewGuidance: 35.00 Mil for Q4 2025
Q1 2026 Non-GAAP Operating Margin 18.0%    
2026 Revenue732.00 Mil737.00 Mil742.00 Mil28.6% Higher NewGuidance: 573.00 Mil for 2025
2026 Non-GAAP Income from Operations151.00 Mil153.50 Mil156.00 Mil43.5% Higher NewGuidance: 107.00 Mil for 2025
2026 Non-GAAP Operating Margin 21.0%    

Insider Activity

Updated 6/29/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Insight, Holdings Group, Llc See footnotesSell629202682.831,466,667  Form
2Insight, Holdings Group, Llc See footnotesSell629202671.82530,982  Form
3Insight, Holdings Group, LlcSee FootnotesSell624202671.67142,311  Form
4Insight, Holdings Group, LlcSee FootnotesSell624202671.15390,917  Form
5Insight, Holdings Group, LlcSee FootnotesSell624202670.21112,477  Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Insight, Holdings Group, Llc See footnotesSell629202682.831,466,667  Form
2Insight, Holdings Group, Llc See footnotesSell629202671.82530,982  Form
3Insight, Holdings Group, LlcSee FootnotesSell624202671.67142,311  Form
4Insight, Holdings Group, LlcSee FootnotesSell624202671.15390,917  Form
5Insight, Holdings Group, LlcSee FootnotesSell624202670.21112,477  Form
6Insight, Holdings Group, LlcSee FootnotesSell624202670.95224,399  Form
7Pursley, JamesPresidentDirectSell623202669.3133,0002,287,25151,352,049Form
8Insight, Holdings Group, Llc See footnotesSell618202670.3665,581  Form
9Robinson, Elliott See footnoteSell61220260.000  Form
10Robinson, Elliott See footnoteSell61220260.000  Form
11Robinson, Elliott See footnoteSell61220260.000  Form
12Mecklenburg, Gabriel MIDirectSell605202665.5450,000  Form
13Robinson, Elliott See footnoteSell60320260.000  Form
14Robinson, Elliott See footnoteSell60320260.000  Form
15Mecklenburg, Gabriel MIDirectSell603202660.2283,334  Form
16Pursley, JamesPresidentDirectSell527202653.7916,000860,60641,966,523Form
17Mecklenburg, Gabriel MIDirectSell527202653.7983,333  Form
18Budge, JamesChief Financial OfficerDirectSell527202653.795,907317,75723,958,791Form
19Budge, JamesChief Financial OfficerDirectSell521202655.3478143,22124,974,555Form
20Robinson, Elliott See footnoteSell51120260.000  Form
21Robinson, Elliott See footnoteSell51120260.000  Form
22Perez, Daniel AntonioCEO & Co-FounderSpouseSell508202655.0545,4562,502,3661,952,634Form
23Mecklenburg, Gabriel MIDirectSell508202655.0150,000  Form
24Perez, Daniel AntonioCEO & Co-FounderSpouseSell508202655.09104,5445,759,1621,953,986Form
25Mecklenburg, Gabriel MIDirectSell422202645.0533,333  Form
26Mecklenburg, Gabriel MIDirectSell402202638.4650,000  Form
27Pursley, JamesPresidentDirectSell324202642.2615,000633,92730,940,048Form
28Budge, JamesChief Financial OfficerDirectSell324202642.2611,006465,13916,965,222Form
29Mecklenburg, Gabriel MIDirectSell310202645.32166,666  Form
30Pursley, JamesPresidentDirectSell224202639.3315,000589,98429,586,931Form
31Budge, JamesChief Financial OfficerDirectSell224202639.3414,763580,73716,526,882Form
32Robinson, Elliott See footnoteSell21720260.000  Form
33Robinson, Elliott See footnoteSell21720260.000  Form
34Perez, Daniel AntonioCEO & Co-FounderDirectSell213202640.26166,665  Form
35Perez, Daniel AntonioCEO & Co-FounderDirectSell106202646.38166,665  Form
36Pursley, JamesPresidentDirectSell1223202548.4015,000725,95037,254,715Form
37Budge, JamesChief Financial OfficerDirectSell1223202548.4110,491507,83721,355,866Form
38Perez, Daniel AntonioCEO & Co-FounderDirectSell1216202548.53166,670  Form
39Robinson, Elliott See footnoteSell120920250.000  Form
40Insight, Holdings Group, Llc See footnotesSell1203202547.761,654,440  Form
41Robinson, Elliott See footnoteSell120120250.000  Form
42Robinson, Elliott See footnoteSell120120250.000  Form
43Budge, JamesChief Financial OfficerDirectSell1125202547.4744,5892,116,77922,781,302Form
44Pursley, JamesPresidentDirectSell1124202545.5715,000683,48735,992,505Form
45Leslie, Kristina MDirectSell1124202545.681,25057,1061,267,753Form
46Budge, JamesChief Financial OfficerDirectSell1121202544.7878134,97323,485,632Form
47Bessemer, Venture Partners X LP See footnoteSell1120202540.05725,00029,036,250135,517,465Form
48Robinson, Elliott See footnoteSell112020250.000  Form
49Leslie, Kristina MDirectSell1119202543.603,813166,2581,264,487Form
50Leslie, Kristina MDirectSell1119202540.462,18788,4761,327,470Form
Core Cache Last Updated: 7/1/2026